ArticleQuantitative imaging in medicine and surgery2025
Application of low-dose FDG-PET/MRI for quantification of lung changes in pediatric patients with cystic fibrosis: a new inflammatory index.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.Annals of the American Thoracic Society · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clinical severity and progression of lung disease in cystic fibrosis (CF) are significantly influenced by the degree of lung inflammation. Non-invasive quantitative diagnostic tools are desirable to differentiate structural and inflammatory lung changes in order to help prevent chronic airway disease. This might also be helpful for the evaluation of longitudinal effects of novel therapeutics. Therefore, the present study assesses the quantification of inflammatory lung changes using positron emission tomography/magnetic resonance imaging (PET/MRI) of the lung in children and adolescents with CF and evaluates the possible impact of PET/MRI on individualized therapy management. Methods: This monocentric, retrospective cohort study included 19 PET/MRI of the lung performed between 2014 and 2021 in 11 patients (16±4.5 years, 8-22 years; 7 females). PET acquisition was performed at least 20 minutes after i.v. application of a weight-adjusted dose of fluor-18-fluorodeoxyglucose ( Results: Uptake was highly increased in 5 cases, moderate in 4 cases, low in 7 cases, no uptake in 3 cases. Most MR-CF score points were assigned to peribronchitis (23%) and air trapping (23%). Metabolically increased lesions were mainly interpreted as consolidations (59%; P<0.001) and mucus plugging (19%, P=0.024). There was a decrease in mean number and volumes of inflammatory lesions (P=0.016 each) and MR-CF score (P=0.047) between baseline and follow-up. After PET/MRI, therapy changed in 18 cases (95%; new medication: 58%, n=11; termination of therapy: 16%, n=3; modification of therapy: 21%, n=4). Conclusions: In selected cases, pulmonary FDG-PET/MRI can help guide therapeutic decision-making and provide complementary information on CF-related lung changes to conventional MRI at a low radiation exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.